Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. RNA Bio/Pharma, Incorporated
WARNING LETTER
•RNA Bio/Pharma, Incorporated•April 11, 2025

RNA Bio/Pharma, Incorporated – FDA Warning Letter, Apr 11, 2025

Record Details

The FDA issued a Warning Letter to RNA Bio/Pharma, Incorporated, following an inspection from April 9 to April 11, 2025, at their Chelan, Washington facility. The letter outlines significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals (21 CFR parts 210 and 211), leading to the conclusion that their drug products are adulterated. The firm had not responded to the initial inspection observations.

Key violations include a systemic failure to adequately test incoming drug components for identity, purity, strength, and quality, and an over-reliance on supplier Certificates of Analysis without validating their reliability. Specifically, the FDA cited the lack of testing for hazardous contaminants like Diethylene Glycol (DEG) and Ethylene Glycol (EG) in high-risk ingredients such as glycerin, and for impurities like methanol and benzene in ethanol, all of which have been linked to severe poisoning incidents globally. Additionally, the company failed to test potentially toxic ingredients such as strychnine, and neglected to perform testing on homeopathic mother tinctures. These deficiencies raise serious concerns about the safety and quality of their oral liquid homeopathic drug products, particularly those intended for children.

To address these critical issues, RNA Bio/Pharma is required to take several actions. These include submitting DEG/EG test results for all high-risk component retains or finished product batches within 30 days, and conducting a full risk assessment for all affected drug products, potentially including recalls and implementing robust corrective and preventive actions for their supply chains. The company must also assess biologic substances for sterility and pathogen contamination, and provide detailed quality control specifications and procedures for future component testing.

Company
RNA Bio/Pharma, Incorporated
Inspection date
April 11, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · bf6370c7-f08e-424e-af8a-a63efc3115e9

Violation Codes8
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.84(d)(1)21 CFR 211.84(d)(2)FD&C Act 501(b)21 CFR 211.34

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore RNA Bio/Pharma, Incorporated
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.